Reuters logo
BRIEF-Bayer's Nexavar submitted to EMA, FDA for thyroid cancer use
July 1, 2013 / 6:36 AM / 4 years ago

BRIEF-Bayer's Nexavar submitted to EMA, FDA for thyroid cancer use

FRANKFURT, July 1 (Reuters) - Bayer AG : * Says sorafenib (nexavar) submitted to the ema and FDA for use in thyroid

cancer

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below